The latter may also have contributed to the results of clinical trials using AAV8 for expression of the human blood coagulation factor IX in hemophilia B patients, in which capsid-specific CD8+ T-cell responses were observed despite the use of CpG-reduced vector genomes (101). Here, F9 is linked to hemophilia B.